G1SecL05: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
Recent developments in vaccines against Lyme Borreliosis emphasize the need to utilize the LA-2 –ospA complex on the basis that it, as a result of its specificity, induces long- term immune response in mice during previously studied clinical trials. Passive immunization of mice that resulted with significant titers of LA-2 serum antibody had a strong correlation with protection against tick transmission of infection<ref>PMID: 23407755</ref>. The LA-2 ospA complex constitutes the interaction between ''Borrelia membrane'' ospA and LA-2 fab, an epitope of the ospA associated with protective immunity after vaccination.<ref name ="quantitative"/> | Recent developments in vaccines against Lyme Borreliosis emphasize the need to utilize the LA-2 –ospA complex on the basis that it, as a result of its specificity, induces long- term immune response in mice during previously studied clinical trials. Passive immunization of mice that resulted with significant titers of LA-2 serum antibody had a strong correlation with protection against tick transmission of infection<ref>PMID: 23407755</ref>. The LA-2 ospA complex constitutes the interaction between ''Borrelia membrane'' ospA and LA-2 fab, an epitope of the ospA associated with protective immunity after vaccination.<ref name ="quantitative"/> | ||
===Structure of LA-2 ospA complex === | |||
==Inefficiency and concerns== | ==Inefficiency and concerns== | ||